- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00243035
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES: Primary I. Determine the maximum tolerated dose and dose-limiting toxicity of tipifarnib when administered with bortezomib in patients with relapsed multiple myeloma. (Phase I) II. Determine the response rate in patients treated with this regimen. (Phase II) III. Determine the toxicity profile of this regimen in these patients. (Phase II)
Secondary I. Determine the progression-free survival of patients treated with this regimen. (Phase II)
Tertiary I. Determine whether this regimen overcomes CAM-DR in primary myeloma cells and establish whether ex vivo efficacy predicts a clinical response in these patients.
II. Determine if activated Akt predicts clinical resistance and if levels of phosphorylated Akt are reduced by tipifarnib and bortezomib in these patients.
III. Determine whether molecular profiles from primary isolates (suspension vs adhered) correlate with clinical response in patients treated with this regimen.
OUTLINE: This is a phase I dose-escalation study of tipifarnib followed by a phase II study.
Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.
Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: Approximately 52-64 patients will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis of multiple myeloma
- Stage II or III disease
Relapsed disease after ≥ 2 prior therapies*, confirmed by the presence of 1 of the following:
- New lytic lesion
- A 25% increase in urine or serum monoclonal protein
- Patients who received prior bortezomib must have responded to therapy
Measurable disease, defined by 1 or more of the following criteria:
- Serum M-component ≥ 1.0 g/dL by serum protein electrophoresis
- Urine M-protein excretion > 200 mg per 24-hour collection, by urine protein electrophoresis
- Performance status - Karnofsky 60-100%
- More than 8 weeks
- Platelet count ≥ 100,000/mm^3
- Absolute neutrophil count ≥ 1,000/mm^3
- Bilirubin ≤ 2 mg/dL
- Direct bilirubin ≤ 2 times upper limit of normal (ULN)
- AST or ALT ≤ 2 times ULN
- Creatinine ≤ 1.5 times ULN
- Calcium ≤ 12 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow study medication
- Capable of following directions regarding study medication, or has a daily caregiver who will be responsible for administering study medication
- No peripheral neuropathy ≥ grade 2
No hypersensitivity to any of the following:
- Bortezomib
- Boron
- Mannitol
- Imidazole compounds (e.g., clotrimazole, ketoconazole, miconazole, econazole)
- No serious medical or psychiatric illness that would preclude study compliance
- No other life-threatening illness (unrelated to tumor)
- No other active or invasive malignancy within the past 3 years except for nonmelanoma skin cancer
- No serious infection
- No prior allogeneic bone marrow transplantation
- More than 30 days since prior and no concurrent immunotherapy
- More than 30 days since prior and no concurrent cytotoxic chemotherapy
- More than 14 days since prior high-dose corticosteroids
- No concurrent therapeutic corticosteroids (e.g., > 10 mg prednisone per day)
- No concurrent hormonal therapy
- No concurrent antiemetic corticosteroids
- More than 14 days since prior and no concurrent radiotherapy
- More than 1 year since prior bortezomib
- More than 14 days since prior investigational drugs
- No prior tipifarnib
- No other concurrent cancer-related treatment
No concurrent administration of the following enzyme-inducing anti-epileptic drugs:
- Phenytoin
- Phenobarbital
- Carbamazepine
- No concurrent magnesium- or aluminum-based antacids within 2 hours before or after tipifarnib administration
- Concurrent pamidronate or other bisphosphonates allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (bortezomib, tipifarnib)
Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD. Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD. |
Correlative studies
Given orally
Given IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of tipifarnib as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 (phase I)
Time Frame: Up to day 21
|
Up to day 21
|
|
Response rate (complete response [CR] + partial response [PR]) determined using the Bladé Response criteria (phase II)
Time Frame: Up to 6 weeks
|
Exact 95% confidence intervals constructed.
|
Up to 6 weeks
|
Toxicities, graded according to the NCI CTCAE v3.0 (phase II)
Time Frame: Up to 2 years
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients overcoming CAM-DR
Time Frame: Prior to therapy
|
An exact 95% confidence interval for that proportion will be computed.
|
Prior to therapy
|
Proportion of patients overcoming CAM-DR
Time Frame: Day 11 of course 1
|
An exact 95% confidence interval for that proportion will be computed.
|
Day 11 of course 1
|
Relationship of overcoming CAM-DR and clinical response
Time Frame: Prior to therapy
|
Compared using a chi-square contingency table test at the two-sided 0.05 significance level.
|
Prior to therapy
|
Relationship of overcoming CAM-DR and clinical response
Time Frame: Day 11 of course 1
|
Compared using a chi-square contingency table test at the two-sided 0.05 significance level.
|
Day 11 of course 1
|
Clinical resistance and levels of phosphorylated Akt
Time Frame: Prior to therapy
|
P-Akt levels both pre and post treatment will be obtained and compared using a paired t test.
Logistic regression will be used with P-Akt activity as independent variable in a logistic regression modeling probability of response.
Odds ratio indicating change in odds of response associated with a unit change in P-Akt level will be computed as well as a 95% confidence interval for that odds ratio.
|
Prior to therapy
|
Clinical resistance and levels of phosphorylated Akt
Time Frame: Day 11 of course 1
|
P-Akt levels both pre and post treatment will be obtained and compared using a paired t test.
Logistic regression will be used with P-Akt activity as independent variable in a logistic regression modeling probability of response.
Odds ratio indicating change in odds of response associated with a unit change in P-Akt level will be computed as well as a 95% confidence interval for that odds ratio.
|
Day 11 of course 1
|
Correlation of molecular profiles from primary isolates with clinical response
Time Frame: Prior to therapy
|
Compared using paired t tests at the 0.05 significance level.
|
Prior to therapy
|
Correlation of molecular profiles from primary isolates with clinical response
Time Frame: Day 11 of course 1
|
Compared using paired t tests at the 0.05 significance level.
|
Day 11 of course 1
|
Progression-free survival (phase II)
Time Frame: Up to 2 years
|
Summarized with Kaplan-Meier curve and related statistics.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Darrin Beaupre, H. Lee Moffitt Cancer Center and Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Bortezomib
- Tipifarnib
Other Study ID Numbers
- NCI-2012-02675 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 7032 (Other Identifier: CTEP)
- MCC-VEL-04-111
- CDR0000446083
- NCI-7032
- VEL-04-111 (Other Identifier: H. Lee Moffitt Cancer Center and Research Institute)
- R01CA083978 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Multiple Myeloma
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States